Semin Vasc Med 2003; 03(1): 061-068
DOI: 10.1055/s-2003-38333
Copyright © 2002 by Thieme Medical Publishers, Inc., 333 Seventh Avenue, New York, NY 10001, USA. Tel.: +1(212) 584-4662

Changes of Hemostatic Variables during Oral Contraceptive Use

Guido Tans1 , Bonno N. Bouma2 , Harry R. Büller3 , Jan Rosing1
  • 1Department of Biochemistry, Cardiovascular Research Institute Maastricht, Maastricht University, Maastricht, The Netherlands
  • 2Thrombosis and Haemostasis Laboratory, Department of Haematology, University Medical Center Utrecht, Utrecht, The Netherlands
  • 3Department of Vascular Medicine, Academic Medical Center, Amsterdam, The Netherlands
Weitere Informationen


27. März 2003 (online)


The use of oral contraceptives (OCs) has been known for many years to affect significantly almost all hemostatic parameters, but the challenge to relate these changes in a meaningful way to OC-induced increased venous thrombotic risk has not been met. New insights indicate that at least part of the answer can be found in the net effect of OC use on the efficacy with which the protein C pathway down-regulates thrombin formation. During OC use the (blood) plasma of a woman becomes resistant to the anticoagulant action of activated protein C (APC). The extent of this so-called acquired APC resistance as determined in a thrombin generation-based assay correlates remarkably well with the risk increases observed in clinical studies. Recent evidence indicates that the prothrombotic effect of the estrogen component ethinylestradiol in combined OC is counteracted by the progestagen component present in these preparations and that third-generation progestagens such as desogestrel or gestodene are less efficient with respect to this than the second-generation progestagen levonorgestrel.


  • 1 Jordan W M. Pulmonary embolism.  Lancet . 1961;  2 1146-1147
  • 2 Hannaford P C, Owen-Smith V. Using epidemiological data to guide clinical practice: review of studies on cardiovascular disease and use of combined oral contraceptives.  Br Med J . 1998;  316 984-987
  • 3 WHO. Effect of different progestagens in low oestrogen oral contraceptives on venous thromboembolic disease. World Health Organization Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception.  Lancet . 1995;  346 1582-1588
  • 4 Farmer R D, Lawrenson R A, Thompson C R, Kennedy J G, Hambleton I R. Population-based study of risk of venous thromboembolism associated with various oral contraceptives.  Lancet . 1997;  349 83-88
  • 5 Vandenbroucke J P, Helmerhorst F M, Bloemenkamp K WM, Rosendaal F R. Third-generation oral contraceptive and deep venous thrombosis: from epidemiologic controversy to new insight in coagulation.  Am J Obstet Gynecol . 1997;  177 887-891
  • 6 Jick H, Kaye J A, Vasilakis-Scaramozza C, Jick S S. Risk of venous thromboembolism among users of third generation oral contraceptives compared with users of oral contraceptives with levonorgestrel before and after 1995; cohort and case-control analysis.  BMJ . 2000;  321 1190-1195
  • 7 Kluft C, Lansink M. Effect of oral contraceptives on haemostasis variables.  Thromb Haemost . 1997;  78 315-326
  • 8 Winkler U H. Blood coagulation and oral contraceptives. A critical review.  Contraception . 1998;  57 203-209
  • 9 Winkler U H. Effects on hemostatic variables of desogestrel- and gestodene-containing oral contraceptives in comparison with levonorgestrel-containing oral contraceptives: a review.  Am J Obstet Gynecol . 1998;  179 S51-S61
  • 10 Kluft C. Effects on haemostasis variables by second and third generation combined oral contraceptives: a review of directly comparative studies.  Curr Med Chem . 2000;  7 585-591
  • 11 Koster T, Rosendaal F R, Reitsma P H. et al . Factor VII and fibrinogen levels as risk factors for venous thrombosis. A case-control study of plasma levels and DNA polymorphisms-the Leiden Thrombophilia Study (LETS).  Thromb Haemost . 1994;  71 719-722
  • 12 Dahlback B, Carlsson M, Svensson P J. Familial thrombophilia due to a previously unrecognized mechanism characterized by poor anticoagulant response to activated protein C: prediction of a cofactor to activated protein C.  Proc Natl Acad Sci U S A . 1993;  90 1004-1008
  • 13 Svensson P J, Dahlbäck B. Resistance to activated protein C as a basis for venous thrombosis.  N Engl J Med . 1994;  330 517-522
  • 14 Voorberg J, Roelse J, Koopman R. et al . Association of idiopathic venous thromboembolism with single point-mutation at Arg506 of factor V.  Lancet . 1994;  343 1535-1536
  • 15 Bertina R M, Koeleman B P, Koster T. et al . Mutation in blood coagulation factor V associated with resistance to activated protein C.  Nature . 1994;  369 64-67
  • 16 Greengard J S, Sun X, Xu X. et al . Activated protein C resistance caused by Arg506Gln mutation in factor Va.  Lancet . 1994;  343 1361-1362
  • 17 Rodeghiero F, Tosetto A. Activated protein C resistance and factor V Leiden mutation are independent risk factors for venous thromboembolism.  Ann Intern Med . 1999;  130 643-650
  • 18 de Visser C M, Rosendaal F R, Bertina R M. A reduced sensitivity for activated protein C in the absence of factor V Leiden increases the risk of venous thrombosis.  Blood . 1999;  93 1271-1276
  • 19 Rosing J, Tans G, Nicolaes G AF. et al . Oral contraceptives and venous thrombosis: different sensitivities to activated protein C in women using second- and third-generation oral contraceptives.  Br J Haematol . 1997;  97 233-238
  • 20 Olivieri O, Friso S, Manzato F. et al . Resistance to activated protein C in healthy women taking oral contraceptives.  Br J Haematol . 1995;  91 465-470
  • 21 Henkens C M, Bom V J, Seinen A J, van der Meer J. Sensitivity to activated protein C; influence of oral contraceptives and sex.  Thromb Haemost . 1995;  73 402-404
  • 22 Vandenbroucke J P, Rosendaal F R. End of the line for "third-generation-pill" controversy?.  Lancet . 1997;  349 1113-1114
  • 23 Spitzer W O. The 1995 pill scare revisited: anatomy of a non-epidemic.  Hum Reprod . 1997;  12 2347-2357
  • 24 Spitzer W O. Bias versus causality: interpreting recent evidence of oral contraceptive studies.  Am J Obstet Gynecol . 1998;  179 S43-S50
  • 25 Winkler U H. Hemostatic effects of third- and second-generation oral contraceptives: absence of a causal mechanism for a difference in risk of venous thromboembolism.  Contraception . 2000;  62 11S--38S
  • 26 Heinemann L AJ, Spitzer W O, Winkler U H. Scientific problems with a noncausal artifact.  Am J Obstet Gynecol . 1998;  178 1105-1106
  • 27 Kluft C. A rebuttal-oral contraceptives and venous thrombosis: reply.  Thromb Haemost . 2001;  85 934-936
  • 28 Kluft C. Renewed interest in haemostasis changes induced by oral contraceptives (OCs).  Thromb Haemost . 2000;  84 1-3
  • 29 Rosing J, Middeldorp S, Curvers J. et al . Low-dose oral contraceptives and acquired resistance to activated protein C: a randomised cross-over study.  Lancet . 1999;  354 2036-2040
  • 30 Meijers J C, Middeldorp S, Tekelenburg W. et al . Increased fibrinolytic activity during use of oral contraceptives is counteracted by an enhanced factor XI-independent down regulation of fibrinolysis: a randomized cross-over study of two low-dose oral contraceptives.  Thromb Haemost . 2000;  84 9-14
  • 31 Middeldorp S, Meijers J C, van den Ende E A. et al . Effects on coagulation of levonorgestrel- and desogestrel-containing low dose oral contraceptives: a cross-over study.  Thromb Haemost . 2000;  84 4-8
  • 32 Tans G, Curvers J, Middeldorp S. et al . A randomized cross-over study on the effects of levonorgestrel- and desogestrel-containing oral contraceptives on the anticoagulant pathways.  Thromb Haemost . 2000;  84 15-21
  • 33 Bajzar L, Manuel R, Nesheim M E. Purification and characterization of TAFI, a thrombin-activable fibrinolysis inhibitor.  J Biol Chem . 1995;  270 14477-14484
  • 34 Redlitz A, Tan A K, Eaton D L, Plow E F. Plasma carboxypeptidases as regulators of the plasminogen system.  J Clin Invest . 1995;  96 2534-2538
  • 35 Wang W, Boffa M B, Bajzar L, Walker J B, Nesheim M E. A study of the mechanism of inhibition of fibrinolysis by activated thrombin-activable fibrinolysis inhibitor.  J Biol Chem . 1998;  273 27176-27181
  • 36 Heeb M J, Rosing J, Bakker H M. et al . Protein S binds to and inhibits factor Xa.  Proc Natl Acad Sci U S A . 1994;  91 2728-2732
  • 37 Hackeng T M, van 't Veer C, Meijers J C, Bouma B N. Human protein S inhibits prothrombinase complex activity on endothelial cells and platelets via direct interactions with factors Va and Xa.  J Biol Chem . 1994;  269 21051-21058
  • 38 Varadi K, Rosing J, Tans G. et al . Factor V enhances the cofactor function of protein S in the APC- mediated inactivation of factor VIII: influence of the factor VR506Q mutation.  Thromb Haemost . 1996;  76 208-214
  • 39 Varadi K, Rosing J, Tans G, Schwarz H P. Influence of factor V and factor Va on APC-induced cleavage of human factor VIII.  Thromb Haemost . 1995;  73 730-731
  • 40 Shen L, Dahlback B. Factor V and protein S as synergistic cofactors to activated protein C in degradation of factor VIIIa.  J Biol Chem . 1994;  269 18735-18738
  • 41 Kluft C, de Maat P M, Heinemann L A, Spannagl M, Schramm W. Importance of levonorgestrel dose in oral contraceptives for effects on coagulation.  Lancet . 1999;  354 832-833
  • 42 Kemmeren J M, Algra A, Meijers J C, Bouma B N, Grobbee D E. Effect of second- and third-generation oral contraceptives on fibrinolysis in the absence or presence of the factor V Leiden mutation.  Blood Coagul Fibrinolysis . 2002;  13 373-381
  • 43 Kemmeren J M, Algra A, Meijers J C, Bouma B N, Grobbee D E. Effects of second and third generation oral contraceptives and their respective progestagens on the coagulation system in the absence or presence of the factor V Leiden mutation.  Thromb Haemost . 2002;  87 199-205
  • 44 Kemmeren J M, Algra A, Meijers J C. et al . Effects of second and third generation oral contraceptives and their respective progestagens on the protein C system in the absence or presence of the factor V Leiden mutation: a randomized trial (submitted for publication). 
  • 45 Curvers J, Thomassen M C, Nicolaes G A. et al . Acquired APC resistance and oral contraceptives: differences between two functional tests.  Br J Haematol . 1999;  105 88-94
  • 46 Curvers J, Thomassen M C, Rimmer J. et al . Effects of hereditary and acquired risk factors of venous thrombosis on a thrombin generation-based APC resistance test.  Thromb Haemost . 2002;  88 5-11
  • 47 Oral contraceptives in the nineties: metabolic aspects-facts and fiction. First European Conference on Sex Steroids and Metabolism. Esbjerg, Denmark, May 18-20, 1989.  Am J Obstet Gynecol . 1990;  163 273-446
  • 48 Consensus Development Meeting: metabolic aspects of oral contraceptives of relevance for cardiovascular diseases.  Am J Obstet Gynecol . 1990;  162 1335-1337
  • 49 Vandenbroucke J P, Rosing J, Bloemenkamp K W. et al . Oral contraceptives and the risk of venous thrombosis.  N Engl J Med . 2001;  344 1527-1535
  • 50 Poort S R, Rosendaal F R, Reitsma P H, Bertina R M. A common genetic variation in the 3′-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis.  Blood . 1996;  88 3698-3703
  • 51 van Hylckama Vlieg A, van der Linden K I, Bertina R M, Rosendaal F R. High levels of factor IX increase the risk of venous thrombosis.  Blood . 2000;  95 3678-3682
  • 52 Meijers J C, Tekelenburg W L, Bouma B N, Bertina R M, Rosendaal F R. High levels of coagulation factor XI as a risk factor for venous thrombosis.  N Engl J Med . 2000;  342 696-701
  • 53 Comp P C, Nixon R R, Cooper M R, Esmon C T. Familial protein S deficiency is associated with recurrent thrombosis.  J Clin Invest . 1984;  74 2082-2088
  • 54 Comp P C, Esmon C T. Recurrent venous thromboembolism in patients with a partial deficiency of protein S.  N Engl J Med . 1984;  311 1525-1528
  • 55 Griffin J H, Evatt B, Zimmerman T S, Kleiss A J, Wideman C. Deficiency of protein C in congenital thrombotic disease.  J Clin Invest . 1981;  68 1370-1373
  • 56 Schwarz H P, Fischer M, Hopmeier P, Batard M A, Griffin J H. Plasma protein S deficiency in familial thrombotic disease.  Blood . 1984;  64 1297-1300
  • 57 Koster T, Rosendaal F R, de Ronde H. et al . Venous thrombosis due to poor anticoagulant response to activated protein C: Leiden Thrombophilia Study.  Lancet . 1993;  342 1503-1506
  • 58 Zöller B, Hillarp A, Berntorp E, Dahlback B. Activated protein C resistance due to a common factor V gene mutation is a major risk factor for venous thrombosis.  Annu Rev Med . 1997;  48 45-58
  • 59 Greaves M, Preston F E. Rebuttal to: oral contraceptives and venous thromboembolism.  Thromb Haemost . 2001;  85 932-936
  • 60 Tans G, Rosendaal F R, Curvers J. et al . APC resistance determined with the endogenous thrombin potential is associated with venous thrombosis: a blinded clinical evaluation.  Thromb Haemost . 1999;  Suppl 202-203
  • 61 Heinemann L AJ, Assmann A, Spannagl M. et al . Normalized activated protein C ratio itself not associated with increased risk of venous thromboembolism.  Contraception . 1998;  58 321-322
  • 62 Thomassen M L G D C, Curvers J, Rimmer J E. et al . Influence of hormone replacement therapy, oral contraceptives and pregnancy on APC-resistance.  Thromb Haemost . 1999;  Suppl 770-771
  • 63 Jick H, Jick S S, Gurewich V, Myers M W, Vasilakis C. Risk of idiopathic cardiovascular death and nonfatal venous thromboembolism in women using oral contraceptives with differing progestagen components.  Lancet . 1995;  346 1589-1593
  • 64 Bloemenkamp K WM, Rosendaal F R, Helmerhorst F M, Buller H R, Vandenbroucke J P. Enhancement by factor V Leiden mutation of risk of deep-vein thrombosis associated with oral contraceptives containing third-generation progestagen.  Lancet . 1995;  346 1593-1596
  • 65 Quehenberger P, Loner U, Kapiotis S. et al . Increased levels of activated factor VII and decreased plasma protein S activity and circulating thrombomodulin during use of oral contraceptives.  Thromb Haemost . 1996;  76 729-734